TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| WakeMed Health & Hospitals to eliminate 85 jobs WakeMed Health & Hospitals plans to cut 85 jobs as part of a cost-cutting move in the face of a $35 million drop in government reimbursements. feeds.bizjournals.com |
Obama Seeks Labor's Support on Health Obama appealed to labor to back his health overhaul. He gave speeches in Ohio and at an AFL-CIO convention, part of a bid for support of his embattled effort. online.wsj.com |
New Conflict Rules at Medical Journals Medical journals will soon require more stringent, uniform reporting of researchers' conflicts of interest. online.wsj.com |
Quest Diagnostics offering cash for senior notes (AP) Medical lab operator Quest Diagnostics Inc. said Thursday it is offering $750 million in notes and will use proceeds to buy back its senior debt. us.rd.yahoo.com |
Micromet: Opportunity Lies in Breakthrough BiTE Antibody In the past Prohost Letter, we highlighted the biotech firm Micromet (MITI) and its extremely elegant BiTE monoclonal antibody technology. The BiTE antibody creates an immunological synapse between the cytotoxic T cells and the cancer cell in the same manner it happens naturally in the body. The cytolytic synapses mediate the delivery of cell poisonous proteins - perforin and granzymes - from the cytotoxic T cells into the cancer cells, leading these cells to self-destruct, a process referred to as apoptosis, or programmed cell death. The concept is elegant. It is a breakthrough. But, like most breakthroughs, the BiTE approach needed to be validated. Slowly, but surely, validation is being made. This validation began with the observation that in the presence of BiTE antibodies, T cells have demonstrated their full cancer killing capability as they have serially eliminated tumor cells. More over, through the killing process, T cells were observed to proliferate, as judged by their increase in number at the site of attack.Complete Story » seekingalpha.com |